Skip to main content
. 2022 Jul 26;2022:3621496. doi: 10.1155/2022/3621496

Figure 3.

Figure 3

The percentages of MDSCs and CD68+CD163+M2-like macrophages of NSCLC patients in various clinical characteristics. (a, b) The proportions of MDSCs and CD68+CD163+M2-like macrophages in NSCLC patients with or without metastasis. (c, d) The percentages of MDSCs and CD68+CD163+M2-like macrophages in NSCLC patients with a different radiotherapy area. (e, f) The proportions of MDSCs and CD68+CD163+M2-like macrophages in NSCLC patients with diverse pathologic types. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001, compared to the HC group in two-tailed Student's t-test. #p < 0.05. The bars denote mean ± SD.